Shanghai Henlius Biotech Co. Ltd. and Shanghai Allist Pharmaceuticals Co., Ltd. led the group of Chinese biotech companies reporting full-year net profits in 2023, boosting confidence in the growing self-sustainability of domestic firms in the sector.
Key Takeaways
-
Three Chinese biotechs - Henlius, Akeso and Harbour Biomed - moved into the black for the first time in 2023.
Previously focused on biosimilars, Henlius last year reversed a money-losing streak to return an annual net profit of CNY546m, due...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?